Xencor Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
260
- Stock Symbol
-
XNCR
- Investments
-
2
- Share Price
-
$34.04
- (As of Thursday Closing)
Xencor General Information
Description
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Contact Information
Website
xencor.comCorporate Office
- 465 North Halstead Street
- Suite 200
- Pasadena, CA 91107
- United States
Corporate Office
- 465 North Halstead Street
- Suite 200
- Pasadena, CA 91107
- United States
Xencor Stock Performance
As of 19-Nov-2026, Xencor’s stock price is $34.04. Its current market cap is $2.55B with 75M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $34.04 | $34.39 | $10.38 - $40.60 | $2.55B | 75M | 1.53M | -$1.56 |
Xencor Financials Summary
As of 30-Sep-2026, Xencor has a trailing 12-month revenue of $200M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,568,772 | 691,517 | 1,147,601 | 858,607 |
| Revenue | 200,494 | 125,576 | 110,493 | 174,615 |
| EBITDA | (103,574) | (74,718) | (218,103) | (121,290) |
| Net Income | (117,862) | (91,923) | (232,618) | (133,133) |
| Total Assets | 770,505 | 875,495 | 951,945 | 965,135 |
| Total Debt | 160,227 | 187,747 | 231,953 | 251,943 |
Xencor Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Xencor Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Xencor Comparisons
Industry
Financing
Details
Xencor Competitors (105)
One of Xencor’s 105 competitors is Macrogenics, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Macrogenics | Formerly VC-backed | Rockville, MD | ||||
| AnaptysBio | Formerly VC-backed | San Diego, CA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| MediGene | Formerly VC-backed | Planegg, Germany |
Xencor Patents
Xencor Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026076317-A1 | Bispecific antibodies that bind to mica/b and cd3 | Pending | 04-Oct-2024 | ||
| US-20260209369-A1 | Anti-tl1a x anti-il23 antibodies | Pending | 09-Sep-2024 | ||
| WO-2026055669-A2 | Anti-tl1a x anti-il23 antibodies | Pending | 09-Sep-2024 | ||
| WO-2026055669-A3 | Anti-tl1a x anti-il23 antibodies | Pending | 09-Sep-2024 | ||
| US-20260070982-A1 | Antigen binding molecules to cd3 and cd19 | Pending | 07-Sep-2024 | A61P35/00 |
Xencor Signals
Xencor Investments (2)
Xencor’s most recent deal was a Early Stage VC with Zenas BioPharma for . The deal was made on 07-Nov-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Zenas BioPharma | 07-Nov-2022 | Early Stage VC | Drug Discovery | ||
| Zenas BioPharma | Early Stage VC | Drug Discovery |
Xencor ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
34.06 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Xencor Exits (2)
Xencor’s most recent exit was on 07-Nov-2022 from Zenas BioPharma. The exit was categorized as with 14 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Zenas BioPharma | 07-Nov-2022 | Completed |
|
||
| Zenas BioPharma | Early Stage VC | Completed |
|
Xencor FAQs
-
When was Xencor founded?
Xencor was founded in 1997.
-
Where is Xencor headquartered?
Xencor is headquartered in Pasadena, CA.
-
What is the size of Xencor?
Xencor has 260 total employees.
-
What industry is Xencor in?
Xencor’s primary industry is Biotechnology.
-
Is Xencor a private or public company?
Xencor is a Public company.
-
What is Xencor’s stock symbol?
The ticker symbol for Xencor is XNCR.
-
What is the current stock price of Xencor?
As of 19-Nov-2026 the stock price of Xencor is $34.04.
-
What is the current market cap of Xencor?
The current market capitalization of Xencor is $2.55B.
-
What is Xencor’s current revenue?
The trailing twelve month revenue for Xencor is $200M.
-
Who are Xencor’s competitors?
Macrogenics, AnaptysBio, Genetix Biotherapeutics, Adaptimmune Therapeutics, and MediGene are some of the 105 competitors of Xencor.
-
What is Xencor’s annual earnings per share (EPS)?
Xencor’s EPS for 12 months was -$1.56.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process